High-dose vitamin D cut new lesions after first MS attack

Credibility

Interest

Share:2 min read

Key Takeaway

High-dose vitamin D reduced new brain lesions after a first MS-like attack, but it did not clearly reduce relapses.

What They Found

Researchers compared high-dose vitamin D with a placebo (a pill with no active treatment). About 60% of the vitamin D group had a relapse or new brain scan activity, compared with about 74% of the placebo group. New brain lesions appeared in about 46% of the vitamin D group and about 59% of the placebo group. Relapses occurred in about 18% and 22% of the groups, but this difference was not clear. Severe health problems occurred in both groups, and none were linked to vitamin D.

Who Should Care and Why

The study included adults in France after a first MS-like attack. They had not started treatment, and their first attack had happened recently. Their blood vitamin D levels were below the study's cutoff. Some participants already met updated criteria for relapsing-remitting MS, which has periods of new symptoms or flare-ups. The findings may matter to people in this early stage because the study measured both brain scan changes and relapses.

Important Considerations

You should know that this randomized trial assigned 316 people to vitamin D or a placebo. You should know that fewer brain lesions did not come with a clear drop in relapses or other clinical outcomes. You should know that researchers said more study is needed on high-dose vitamin D alongside other treatment.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Clinical Trials Treatment Updates

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like JAMA often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News